Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles

Subbaya Subramanian, Robert B. West, Christopher Corless, Wenbin Ou, Brian P. Rubin, Kent Man Chu, Suet Yi Leung, Siu Tsan Yuen, Shirley Zhu, Tina Hernandez-Boussard, Kelli Montgomery, Torsten O. Nielsen, Rajiv M. Patel, John R. Goldblum, Michael Heinrich, Jonathan A. Fletcher, Matt Van De Rijn

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated.

Original languageEnglish (US)
Pages (from-to)7780-7790
Number of pages11
JournalOncogene
Volume23
Issue number47
DOIs
StatePublished - Oct 14 2004

Fingerprint

Gastrointestinal Stromal Tumors
Transcriptome
Mutation
Exons
Genes
70-kDa Ribosomal Protein S6 Kinases
Receptor Protein-Tyrosine Kinases
Gene Expression Profiling
Oncogenes
Immunoblotting
In Situ Hybridization
Cluster Analysis
Neoplasms
Stomach
Phosphotransferases
Immunohistochemistry
RNA
Imatinib Mesylate

Keywords

  • Gene expression
  • GIST
  • KIT
  • Microarray
  • Mutations
  • PDGFRA

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Subramanian, S., West, R. B., Corless, C., Ou, W., Rubin, B. P., Chu, K. M., ... Van De Rijn, M. (2004). Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene, 23(47), 7780-7790. https://doi.org/10.1038/sj.onc.1208056

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. / Subramanian, Subbaya; West, Robert B.; Corless, Christopher; Ou, Wenbin; Rubin, Brian P.; Chu, Kent Man; Leung, Suet Yi; Yuen, Siu Tsan; Zhu, Shirley; Hernandez-Boussard, Tina; Montgomery, Kelli; Nielsen, Torsten O.; Patel, Rajiv M.; Goldblum, John R.; Heinrich, Michael; Fletcher, Jonathan A.; Van De Rijn, Matt.

In: Oncogene, Vol. 23, No. 47, 14.10.2004, p. 7780-7790.

Research output: Contribution to journalArticle

Subramanian, S, West, RB, Corless, C, Ou, W, Rubin, BP, Chu, KM, Leung, SY, Yuen, ST, Zhu, S, Hernandez-Boussard, T, Montgomery, K, Nielsen, TO, Patel, RM, Goldblum, JR, Heinrich, M, Fletcher, JA & Van De Rijn, M 2004, 'Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles', Oncogene, vol. 23, no. 47, pp. 7780-7790. https://doi.org/10.1038/sj.onc.1208056
Subramanian, Subbaya ; West, Robert B. ; Corless, Christopher ; Ou, Wenbin ; Rubin, Brian P. ; Chu, Kent Man ; Leung, Suet Yi ; Yuen, Siu Tsan ; Zhu, Shirley ; Hernandez-Boussard, Tina ; Montgomery, Kelli ; Nielsen, Torsten O. ; Patel, Rajiv M. ; Goldblum, John R. ; Heinrich, Michael ; Fletcher, Jonathan A. ; Van De Rijn, Matt. / Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. In: Oncogene. 2004 ; Vol. 23, No. 47. pp. 7780-7790.
@article{b8c00fcc330b48b48949b04729012498,
title = "Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles",
abstract = "Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated.",
keywords = "Gene expression, GIST, KIT, Microarray, Mutations, PDGFRA",
author = "Subbaya Subramanian and West, {Robert B.} and Christopher Corless and Wenbin Ou and Rubin, {Brian P.} and Chu, {Kent Man} and Leung, {Suet Yi} and Yuen, {Siu Tsan} and Shirley Zhu and Tina Hernandez-Boussard and Kelli Montgomery and Nielsen, {Torsten O.} and Patel, {Rajiv M.} and Goldblum, {John R.} and Michael Heinrich and Fletcher, {Jonathan A.} and {Van De Rijn}, Matt",
year = "2004",
month = "10",
day = "14",
doi = "10.1038/sj.onc.1208056",
language = "English (US)",
volume = "23",
pages = "7780--7790",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "47",

}

TY - JOUR

T1 - Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles

AU - Subramanian, Subbaya

AU - West, Robert B.

AU - Corless, Christopher

AU - Ou, Wenbin

AU - Rubin, Brian P.

AU - Chu, Kent Man

AU - Leung, Suet Yi

AU - Yuen, Siu Tsan

AU - Zhu, Shirley

AU - Hernandez-Boussard, Tina

AU - Montgomery, Kelli

AU - Nielsen, Torsten O.

AU - Patel, Rajiv M.

AU - Goldblum, John R.

AU - Heinrich, Michael

AU - Fletcher, Jonathan A.

AU - Van De Rijn, Matt

PY - 2004/10/14

Y1 - 2004/10/14

N2 - Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated.

AB - Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated.

KW - Gene expression

KW - GIST

KW - KIT

KW - Microarray

KW - Mutations

KW - PDGFRA

UR - http://www.scopus.com/inward/record.url?scp=7644242712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7644242712&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1208056

DO - 10.1038/sj.onc.1208056

M3 - Article

VL - 23

SP - 7780

EP - 7790

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 47

ER -